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The aim of the present study was to assess the expression of miRNAs in the Vitreous
Humor (VH) of patients with Macular Hole (MH) and Epiretinal Membrane (ERM) compared
to a control group.
Methods
In this prospective, comparative study, 2-ml of VH was extracted from the core of the vitre-
ous chamber in consecutive patients who underwent standard vitrectomy for ERM and MH.
RNA was extracted and TaqMan® Low Density Arrays (TLDAs) were used to profile the tran-
scriptome of 754 miRNAs. Results were validated by single TaqMan® assays. Finally, we
created a biological network of differentially expressed miRNA targets and their nearest
neighbors.
Results
Overall 10 eyes with MH, 16 eyes with idiopathic ERM and 6 controls were enrolled in the
study. Profiling data identified 5 miRNAs differentially expressed in patients affected by MH
and ERM with respect to controls. Four were downregulated (miR-19b, miR-24, miR-155,
miR-451) and 1 was downregulated (miR-29a); TaqMan® assays of the VH of patients
affected by MH and ERM, with respect to controls, showed that the most differentially
expressed were miR-19b (FC -9.13, p:<0.00004), mir-24 (FC -7.52, p:<0.004) and miR-142-
3p (FC -5.32, p:<0.011). Our network data showed that deregulation of differentially
expressed miRNAs induces an alteration of several pathways associated with genes
involved in both MH and ERM.
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Conclusion
The present study suggests that disregulation of miR-19b, miR-24 and miR-142-3p, might
be related to the alterations that characterize patients affected by MH and ERM.
Introduction
Vitreo maculopathies are characterized by traction exerted on the macula generated by the vit-
reous and the inner limiting membrane of the retina. Traction arising from vitreomacular
adhesions can be tangential or perpendicular to the retinal surface. Both conditions might
determine features of clinical pathologies including epiretinal membrane (ERM) and macular
hole (MH); in these diseases epiretinal cell proliferations and fibrosis are essential parts of the
pathogenesis [1–2].
Most MHs are idiopathic, however, they can also be found in highly myopic eyes, or after a
ocular trauma [3]. Pseudoholes, secondary to ERMs, should be differentiated from full thick-
ness MHs [4]. ERMs are detected in about two-thirds of eyes affected by MHs [5–6].
ERM can be idiopathic or secondary to several vitreoretinal diseases and is characterized by
cellular contraction after fibrocellular proliferation on the inner limiting membrane. Posterior
vitreous detachment (PVD) can injure the internal limiting membrane, allowing movement of
glial cells to the retinal surface. Furthermore, an incomplete PVD might provide appropriate
conditions for fibrocellular proliferation in the area between the vitreous and the retina [7]. In
the process of ERM formation, extracellular matrix, cytokines and growth factors are involved
in cellular signal transmission and in tissue changes [8].
Some studies have shown that a number of regulatory factors have also significant effects
on fibrosis and may be related to its inter-organ variability [9].
miRNAs are small, non-coding RNAs with a strictly regulated biogenesis. This is combined
with an extremely flexible and sophisticated regulatory function, allowing simultaneous target-
ing of multiple mRNAs coding for proteins involved in different, crucial biological pathways
of specific cell types and tissues [10].
miRNAs exert control over cellular processes such as differentiation and proliferation act-
ing on various targets [11], and may play the role of conductors in the pathogenesis of fibrosis
[12].
miRNA alterations are common in different fibrotic disorders such as systemic sclerosis
[13], liver cirrhosis [14], cardiac fibrosis [15–16], chronic kidney disease [17], and idiopathic
pulmonary fibrosis [18].
The discovery, in 2008, of miRNAs circulating in human blood opened new intriguing per-
spectives in molecular diagnosis [19,20]. Circulating miRNAs have been shown to be present
in several biological fluids (e.g., serum, plasma, cerebrospinal fluid, vitreous humor) in a stable
form that prevents their digestion by RNases. However, little is known about the origin and
function of circulating miRNAs. One of the most fascinating hypotheses is that extracellular
miRNAs may work as mediators of cell-cell communication: specific miRNAs are selectively
secreted by donor cells to be functionally transferred to recipient cells [21,22]. Currently, two
major release mechanisms of circulating miRNAs have been proposed: (i) secretion of miR-
NAs stored inside microvesicles or exosomes [23]; (ii) secretion of miRNAs complexed to
ribonucleoproteins [24]. Since concentration of circulating miRNAs is related to the physio-
logical and pathological condition of patients, it is not surprising that they have already been
exploited as molecular biomarkers for neoplastic and degenerative diseases.
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Our group previously showed the presence of miRNAs in the Vitreous Humor (VH) and
that the expression of circulating miRNAs in VH is altered in different eye diseases [25,26].
Recent reviews have addressed the role of miRNAs in fibrosis with a focus on organ-specific
miRNA alteration [27–30] and both pathologies are caused by mechanisms related to fibrosis.
The aim of the present study was to assess the expression of miRNAs in the VH of patients
with MH and ERM compared to a control group.
Methods
This prospective, comparative study included all consecutive eyes of patients who underwent
vitrectomy at the Ophthalmic Clinic of the University of Catania, for MH and ERM, between
September 2015 and April 2016. Controls were all consecutive eyes of patients, matched by age
and sex, who underwent vitrectomy for primary symptomatic idiopathic floaters in the same
period.
Floaters represent the least compromised condition for eyes to undergo vitreous surgery,
since it is not possible to remove the vitreous from living healthy subjects.
The study adhered to the tenets of the Declaration of Helsinki and was approved by the
Local Ethics Research Committee (“Comitato Etico Catania1”). Before the procedures, written
informed consent was obtained from all participants in the study.
All eyes had idiopathic MHs with a minimum size > 250 μm [31] and idiopathic fovea-
involving ERM, with prominent thickening of the inner retinal layer [32]. Both MHs and
ERM were diagnosed ophthalmoscopically and with a Spectralis Optical Coherence Tomogra-
phy (OCT) examination (Heidelberg Engineering, Heidelberg, Germany).
We excluded from our study patients with diabetes, cardiovascular failure, autoimmune
diseases, renal or hepatic failure, Alzheimer’s, and Parkinson’s disease. We also excluded
patients who had undergone previous ocular surgical procedures, affected by glaucoma, uve-
itis, diabetic retinopathy and other retinopathies, ocular trauma, and any ocular tumor, as the
amount of vitreal miRNAs could be modified, depending on the diseases of the eye [25].
All patients underwent a 3-port 25-gauge vitrectomy performed by the same surgeon (M.
R.) under local anesthesia. The Resight 700 (Carl Zeiss Meditec AG, Jena, Germany) wide-
angle viewing system or the Binocular Indirect Ophthalmol Microscope wide-angle viewing
system (BIOM; Oculus Inc, Wetzlar, Germany) were used. Sclerotomies were placed at 3.5
mm to the limbus and performed in a 30˚ fashion, parallel to the limbus [33]. With closed infu-
sion, a 2-ml vitreous specimen was extracted from the core of the vitreous cavity into a syringe
using a three-way tap. The extracted vitreous was then placed in a sterile container, and the vit-
rectomy continued as normal. Samples were centrifuged at 700 ×g for 10’ to pellet and elimi-
nate any circulating cells and finally stored at -80˚C until analysis.
RNA extraction
Using a Qiagen miRNeasy Mini Kit (Qiagen, GmbH, Hilden, Germany), RNA was extracted
from 500-μl vitreous samples. RNA was eluted in a 30 μl volume of elution buffer with two
repeated steps in the same collection tube. RNAs were quantified by fluorometery (Qubit, Invi-
trogen) and spectrophotometery (GeneQuant Pro, BioChrom Ltd, Cambridge, UK).
miRNA expression analysis
According to the manufacturer’s instructions, 4.5 μl of vitreal RNAs were retrotranscribed and
preamplified to profile the transcriptome of 754 miRNAs, and then loaded on TaqMan1 Low
Density Arrays (TLDAs) TaqMan1 Human MicroRNA Array v3.0 A and B (Applied Biosys-
tems, Foster City, CA, USA). PCRs on TLDAs were conducted on a 7900HT Fast Real Time
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PCR System (Applied Biosystems). Results were validated by single TaqMan1 assays and Taq-
Man1 Universal Master mix II (Life Technologies, Italy) using 20 ng of vitreal RNA, according
to the manufacturer’s instructions.
Statistical analysis
To obtain an accurate miRNA profiling, we used the global median normalization method, as
previously reported for the same kind of analysis [26]. By this approach, we identified small
RNAs that presented an expression profile near to the median of TLDAs, i.e. snRNA U6 and
miR-223. Accordingly, they were then used as reference genes for analysis of TLDAs. By Sig-
nificance Analysis of Microarrays (SAM), differentially expressed miRNAs were identified,
computed by Multi experiment viewer v4.8.1, by applying a two-class unpaired test among
ΔCts and using a p-value based on 100 permutations; imputation engine: K-nearest neighbors
(10 neighbors); false discovery rate< 0.05 was used as correction for multiple comparisons.
The 2−ΔΔCT method was used to calculate the Expression fold changes (FC). SnRNA U6 was
used as reference gene for single TaqMan1 validation assays. The unpaired t-test (p< 0.05)
was applied to statistically evaluate the expression differences between patients and healthy
controls by single TaqMan1 validation assays. Statistical significance was established at a p-
value > 0.05. ΔCts for differentially expressed miRNAs with respect to endogenous control
snRNA U6 were used to generate a receiver operating characteristic (ROC) curve (MedCalc
15.11.4). The area under the curve (AUC) and 95% confidence intervals were calculated to
assess the accuracy of each parameter (sensitivity and specificity) and to find an appropriate
cut-off point. Statistical significance of ROC curves was established at a p-value > 0.05.
Network construction and analysis
To evaluate the biological meaning of differentially expressed miRNAs, we retrieved their
experimentally validated targets from miRTarBase (http://mirtarbase.mbc.nctu.edu.tw/). To
statistically enrich the gene signaling regulated by differentially expressed miRNAs, we built a
network based on interactions between differentially expressed miRNA targets and their near-
est neighbors. This network was generated using Cytoscape v2.8.3 (www.cytoscape.org/) and
MiMI plugin (http://mimiplugin.ncibi.org/). We determined statistical over-representation of
pathways by using the FatiGO tool (http://babelomics3.bioinfo.cipf.es) on the genes from the
previously generated network that screened Gene Ontology (GO), KEGG and Reactome data-
bases. Statistical over-representation was calculated by using Fisher’s exact test; Benjamini &
Hochberg FDR Correction; p 0.005. The over-represented pathways in this analysis were
associated with dysregulated genes involved in ERM and MHs, as reported in the literature
(https://www.ncbi.nlm.nih.gov/pubmed/).
Results
Comparison of vitreal miRNA profiles from patients affected by MHs and ERM with those of
controls was performed.
VH samples were extracted from 32 eyes after surgery: 10 eyes with MHs) (mean age 60±6),
16 eyes affected by ERM (mean age 59±5) and 6 controls (mean age 60±7). Eighteen (56%)
were male and 14 (44%) female.
Using TLDA technology, we determined the profiles of 754 miRNAs in the VH, from 4
MHs, 4 ERMs and 4 controls (Ct data are reported in supplementary material 1). The compari-
son of miRNA profiles in the VH of different patient classes by SAM statistical method showed
9 differentially expressed miRNAs (Table 1).
miRNAs in idiopathic epiretinal membrane and macular hole
PLOS ONE | https://doi.org/10.1371/journal.pone.0174297 March 22, 2017 4 / 13
More specifically, we found 4 downregulated miRNAs (miR-19b, miR-24, miR-155, miR-
451) and 1 upregulated miRNA (miR-29a) in patients affected by MH and ERM with respect
to controls; while, 2 downregulated miRNA (miR-29a, miR-142-3p) and 3 upregulated
miRNAs (miR-30a-3p, miR-574-3p, miR-1290) were found by comparing ERMs to MHs
(Table 1). Profiling data showed that 4/5 of differentially expressed miRNAs had a negative
FC, suggesting a general trend of downregulation of circulating miRNAs in the VH of eyes
with MH and ERM with respect to controls. miR-30a-3p, miR-574-3p, miR-1290 were statisti-
cally more abundant in the VH of ERM patients than MH patients.
Validation by single TaqMan® assays
Expression of differentially expressed miRNAs identified by TLDAs was confirmed by single
TaqMan1 assays in the VH of all the patients and controls (Table 2) (Fig 1) (S1 File).
Table 1. Nine differentially expressed miRNAs.










Differentially Expressed vitreal miRNAs by TLDAs (TaqMan Low Density Arrays) in the vitreous humor of
patients affected by macular hole and epiretinal membrane with respect to controls and comparison between
pathological classes.
All Differentially Expressed miRNAs showed a false discovery rate < 0.05 based on Significance Analysis of
Microarray test
FC, Fold Change; Cs, Controls; NDE, Not Differentially Expressed.
https://doi.org/10.1371/journal.pone.0174297.t001
Table 2. Differentially expressed vitreal miRNAs.
DE miRNAs ERM + MH vs Cs MH vs Cs ERM vs Cs ERM vs MH
FC t-test FC t-test FC t-test FC t-test
miR-19b -9.13 0.00004 -14.1 0.002 -6.29 0.0004 2.24 0.046
miR-24 -7.52 0.004 -11.58 0.012 -6.38 0.016 - NS
miR-29a - NS - NS - NS -1.94 0.031
miR-30a-3p - NS - NS - NS 11.08 0.026
miR-142-3p 5.32 0.011 5.81 0.048 4.83 0.021 3.31 0.013
miR-155 6.88 0.018 7.21 0.015 6.45 0.019 - NS
miR-451 6.52 0.041 5.35 0.045 6.96 0.038 - NS
miR-574-3p - NS -7.55 0.018 - NS 7.48 0.047
miR-1290 -6.29 0.036 -8.14 0.031 -5.74 0.042 - NS
Differentially Expressed vitreal miRNAs by single TaqMan® assays in the vitreous humor of patients affected by macular hole and epiretinal membrane with
respect to controls and comparison between pathological classes.
t test: significant p-value < 0.05.
FC, Fold Change; Cs, Controls; NS, Not Significant.
https://doi.org/10.1371/journal.pone.0174297.t002
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The downregulation of miR-19b in the VH of pathological patients with respect to controls
was statistically confirmed by applying the t-test, but we also detected its upregulation in
ERMs with respect to MHs (Table 2) (Fig 1). The downregulation of miR-24 and miR-1290
and the upregulation of miR-142-3p, miR-155 and miR-451 in ERMs and MHs compared
to controls was also validated (Table 2) (Fig 1). Moreover, miR-142-3p, miR-30a-3p, miR-
574-3p were statistically more abundant in ERMs with respect to MHs; while miR-29a was
Fig 1. Box Plots of differentially expressed miRNAs. Box Plots from Single TaqMan® Assays on TaqMan® Low Density Arrays (TLDA) of differentially
expressed miRNAs. Validation by single TaqMan® assays of differentially expressed miRNAs identified by TLDAs in the vitreous humor of all the patients
and controls. Values on the y-axis are reported as ΔCt × (−1).
https://doi.org/10.1371/journal.pone.0174297.g001
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downregulated in the same comparison (Table 2) (Fig 1). We obtained no statistical validation
on the upregulation of miR-29a in patients affected by MHs and ERMs with respect to
controls.
Network and pathway enrichment analysis
To understand the potential functional effect of deregulation of the 9 differentially expressed
miRNAs we created a biological network based on differentially expressed miRNA targets and
their nearest neighbors. Considering all network nodes, we analyzed the statistical over-repre-
sentation of biological pathways from various databases (i.e. Reactome, KEGG, and GO)
against the whole genome (Fig 2).
Our data showed that observed miRNA deregulation could induce an alteration of several
pathways recently associated with genes involved in vitreoretinal diseases, such as MHs, and
ERMs.
ROC curves
To evaluate the discriminating power of the differentially expressed vitreal miRNAs as poten-
tial markers of ERMs and MHs, we computed the ROC curves for each type of comparison:
ERMs + MHs vs controls, ERMs vs controls, MHs vs controls, ERMs vs MHs. Our analysis
showed significant results for just three of the 9 differentially expressed miRNAs: miR-19b,
miR-24 and miR-142-3p. More specifically, we found for ERMs + MHs vs controls that miR-
19b had an AUC of 0.979 (95% CI, 0.810–1; p< 0.0001) with 93.75% sensitivity and 100% spec-
ificity (DCt cut-off value:>14.935); miR-24 showed an AUC of 0.865 (95% CI, 0.652–0.971;
p< 0.0001) with 75% sensitivity and 83.33% specificity (DCt cut-off value: > 14.734); miR-
142-3p had an AUC of 0.857 (95% CI, 0.622 0.973; p< 0.0009) with 78.57% sensitivity and
80% specificity (DCt cut-off value: 0.63348) (Fig 3A–3C). From the comparison of ERMs vs
controls we obtained for miR-19b an AUC of 0.97 (95% CI, 0.755 1; p< 0.0001) with 90.91%
sensitivity and 100% specificity (DCt cut-off value:>14.935); miR-24 had an AUC of 0.848
(95% CI, 0.595–0.973; p<0.0003) with 72.73% sensitivity and 83.33% specificity (DCt cut-off
value:> 14.734); miR-142-3p showed an AUC of 0.933 (95% CI, 0.618 0.999; p< 0.0001) with
83.33% of sensitivity and 100% of specificity (DCt cut-off value: -1.535) (Fig 3D–3F). In the
comparison of MHs vs controls, miR-19b showed an AUC of 1 (95% CI, 0.715 1; p< 0.0001)
with 100% sensitivity and 100% specificity (DCt cut-off value: > 14.935); while, miR-24 had an
AUC of 0.9 (95% CI, 0.576 0.997; p< 0.0001) with 80% sensitivity and 83.3% specificity (DCt
cut-off value:> 14.734) (Fig 3G and 3H). We found no significant result for the comparison of
ERMs vs MHs. These data suggested that the expression of vitreal miRNAs miR-19b, miR-24
and miR-142-3p was able to distinguish ERM and MH eyes from controls, but could not dis-
criminate ERMs from MHs.
Discussion
The results of this study show that in the VH of patients with MHs and ERM smicroRNAs
have different levels of expression, and, in particular, miR-19b, miR-24 and miR-142-3p
exhibit the most significant discriminative power compared to controls.
A decreased expression of miR-19b has been associated with the phenomena of fibrosis in
liver and heart cells [34,35]. In addition, its decreased serum level has been reported in associa-
tion with intestinal fibrosis [36].
Even the downregulation of miR-24 has been repeatedly associated with an increase of
mechanisms of fibrosis in the heart [37,38].
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Fig 2. Biological processes controlled by miR-19b, miR-24 and miR-142-3p network. Overrepresented
biological functions from a molecular network built on validated targets of differentially expressed miRNAs,
retrieved from different annotation databases (GO, KEGG, Reactome). On the left of each histogram the
overrepresented pathways are reported, while on the right the corresponding associated genes to MHs and
ERMs based on literature data are shown. Data are plotted as—log10 of p-values for each biological process.
https://doi.org/10.1371/journal.pone.0174297.g002
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Recent studies demonstrated that miRNAs derived from the miR-17-92 cluster (including
miRNA-19b) directly modulate TGFβ signaling [39,40]. Also the miRNA-24 cluster has been
reported to change TGFβ signaling through several pathways [41,42], suggesting a significant
role of these miRNAs in TGFβ-mediated fibrogenesis.
Fig 3. Receiver Operator Characteristic (ROC) curves for vitreal miR-19b, miR-24 and miR-142-3p in patients affected by MHs and ERMs. ROC
curves of miR-19b (A), miR-24 (B), miR-142-3p (C) DCts in comparison with ERMs + MHs vs controls; miR-19b (D), miR-24 (E), miR-142-3p (F) DCts in
comparison with ERMs vs controls; miR-19b (D), miR-24 (E) in comparison with MHs vs controls. Curves represent DCts calculated by using U6 as
endogenous control.
https://doi.org/10.1371/journal.pone.0174297.g003
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Data in the literature show that overexpression of miRNA-19b and miRNA-24 may be a
valuable therapeutic agent for TGFβ-mediated fibrosis [11].
Increased serum levels of miR-142-3p were associated with the presence and severity of
scleroderma, an autoimmune disease that causes a progressive fibrotic tissue formation in the
normal tissue architecture of various organs [36,43].
Furthermore, the increased levels of this microRNA in biopsies and lymphocytes have been
associated with the presence of interstitial fibrosis as a result of kidney transplants [44].
It has also been shown that miR-142-3p modulates the production of cAMP and is involved
in the regulation of macrophages and T cells [45]. Regulatory T cells lose their capacity to sup-
press immunological processes involving the kidney as suggested by the high levels of miR-
142-3p in tissue samples of renal allografts [37]. Soltaninejad et al. found increased levels of
miR-142-3p in allograft tissues of patients affected by interstitial fibrosis and tubular atrophy
that is the major cause of renal transplant [37].
Downregulation of miR-19b and miR-24 and upregulation of miR-142-3p, already reported
in the literature, are in agreement with the variations observed in our study in the VH of
patients affected by MHs and ERMs and suggest that, as demonstrated in other pathologies,
the different expression of these molecules is related to an increase of fibrosis, which is a char-
acteristic feature of both MHs and ERMs [4–8].
Moreover, to understand the potential functional role of miRNAs differentially expressed
in the VH, we performed a computational analysis on the network of the differentially
expressed miRNA targets. Interestingly, among the functions significantly over-represented in
both the vitreoretinal diseases, one of the most significant is related to TGF-β that has been
linked to fibrogenesis [11].
To date, no approved treatments for fibrosis have been described. Several studies have
described modifications in miRNA expression profiles during development of fibrosis that
control wound-healing transcripts [46]. Wang et al. reported that in vivo, miR-24 could
improve heart function and attenuate fibrosis in the infarct border zone of the heart two weeks
after myocardial infarction through intramyocardial injection of Lentiviruses [34].
To the best of our knowledge, this is the first report describing a possible correlation
between miRNAs and fibrotic phenomena that characterize patients affected by MHs and
ERMs.
The main limitation of our study is the low number of patients and that the control group
presented some vitreous abnormalities (symptomatic vitreous floaters). In particular, the low
number of biologically independent replicates as well as the mixed presence of already-existing
vitreous opacities in the control group might justify the wide dispersion highlighted in the
expression of different miRNAs.
The source of miRNAs in the VH, as in other bodily fluids, could represent a critical point of
debate. The most accepted hypothesis asserts that miRNAs are actively secreted in membrane-
bounded-vesicles (i.e., exosomes), even if some studies suggest that most circulating miRNAs
are in a non-membrane bound form, but rather assembled in ribonucleoprotein complexes
(e.g., Ago2, or other RNA binding proteins) [47]. The hypothesis that circulating miRNAs are
passively released into the extracellular environment as byproducts of dead cells has not been
suitably untangled [24]. Moreover, miRNAs are rapidly degraded by RNases when secreted in
blood without protection by vesicles or ribonucleoprotein complexes [19]. Accordingly, the
real-time PCR dosage of circulating miRNAs resulting from physiologic and pathological flak-
ing of the cells would be scarcely appreciable or extremely variable. Our data on miRNA disre-
gulation in the VH exclude RNA contamination from the few cells floating in the vitreous (i.e.,
phagocytes, hyalocytes of Balazs) because VH samples were appropriately centrifuged to pellet
and remove any circulating cells before RNA extraction (see Methods). Moreover, in our
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previous work we demonstrated that exosomes floating in the VH have miRNA expression pro-
files statistically related to those observed in total VH [26]. These data suggested that the con-
centration of circulating miRNAs in the VH could be mostly, but not exclusively, due to the
molecular content of VH exosomes. For this reason, we believe that vitreal miRNAs, detected as
being altered in MHs and ERMs, may be the result of a dysregulated signaling carried by exo-
somes secreted by the epithelial cells of the retina or from floating cells in the vitreous cavity.
Disregulation of miR-19b, miR-24 and miR-142-3p, might be related to the pathological alter-
ations that characterize patients affected by MHs and ERMs. The concentrations of these vitreal
miRNAs also discriminated pathological eyes from controls, but they were not able to distin-
guish between MHs and ERMs. However, these results would suggest the possibility to exploit a
possible ocular pharmaceutical RNA-based treatment against these differentially expressed
miRNAs that might be administered to the patients affected by these slow-developing alter-
ations, reducing invasive therapeutic approaches, such as vitrectomy.
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